Derivatives of cyclohexane, preparations containing them and their use

Abstract: Derivatives of cyclohexane of the structural formula (I) have been produced in either acid or ester or salt form with high purity. The compounds can be used in the form of compositions for pharmaceutical applications, as food additives and as stabilizers. The use of the compounds for the making of medicaments is also disclosed.

Description: Field of invention The present invention relates to novel derivatives of cyclohexane and compositions containing the same. Background of the invention The family of isomeric hexahydroxy derivatives of cyclohexane are known as inositols. There exist nine different isomers and one of these, myo-inositol, is of biological importance. Chiro-inositols and scyllo-inositols are also of natural occurence, but nothing is known of their biological role. Myo-inositol is an essential nutrient for microorganisms and under special dietary condition for different animals. There are some known derivatives of myo-inositol, such as phosphates and phospholipids. Myo-inositol is found in plants principally as its hexaphosphateester, called phytic acid. It is further known that derivatives with a lower number of phosphate groups are formed during germination. The final products of the germination are myo-inositol and inorganic phosphate. One specific isomer of myo-inositoltriphosphate i.e. D-myo-inositol-1.4.5-triphosphate has been reported in Biochem. Biophys. Res. Commun. 120.2 (1984) p. 481. This compound is known as an intracellular calcium mobilizer in mammalian cells. Other specific isomers of myo-inositoltriphosphate have been disclosed in the Swedish patent appln. No. 8504968-2. Phospholipids are components of cell membranes. One type of phospholipids is the phosphoinositides in which myo-inositol is covalently linked to derivatives of glycerol. Some methyl ethers of myo-inositol occur in plants. The most common one is the 5-methyl ether called seqnoyitol. Summary of the invention According to the present invention, it has quite unexpectedly been possible to produce novel derivatives of cyclohexane in substantially pure form. Detailed description of preferred embodiments According to the invention, esters or ethers of myo-inositol phosphate of the structural formula have been produced with high purity, wherein: R 1 , R 2 and R 3 are the same or different and are (a) hydroxyl (b) where A is (1) a straight or branched chain alkyl containing 1 to 24 carbon atoms, (2) cycloalkyl containing 3 to 16 carbon atoms, (3) alkenyl containing 2 to 24 carbon atoms, (4) cycloalkenyl containing 5 to 16 carbon atoms, (5) aryl containing 6 to 24 carbon atoms, (6) aralkyl, alkaryl, aralkenyl or alkenylaryl wherein alkyl, aryl and alkenyl are as previously defined, (7) a heterocyclic group containing at least one atom of oxygen, nitrogen or sulfur. Said meanings (1) to (7) of A being unsubstituted or substituted with hydroxy, oxo, alkoxy, aryloxy, halo, cyano, isocyano, carboxy, amino, formyl, acyl, acyloxy, acylamino, sulfinyl, sulfonyl, phosphino, phosphinyl, phosphonyl, mercapto, alkylthio, arylthio, silyl, silyloxy, silylthio, nitro or azido; (8) carboxy (9) amino (c) D, where D is (1) an amino acid (2) a peptide or (3) a protein including a lipoprotein and a nucleoprotein (d) E, where E is (1) carbamoyl (2) sulfinyl or sulfonyl (3) xanthate or phosphorothioate (e) -O-B, where B is (1) straight or branched chain alkyl containing 1 to 24 carbon atoms, (2) cycloalkyl containing 3 to 16 carbon atoms, (3) alkenyl containing 2 to 24 carbon atoms, (4) cycloalkenyl containing 5 to 16 carbon atoms, (5) aryl containing 6 to 24 carbon atoms, (6) aralkyl, alkaryl, aralkenyl or alkenylaryl wherein said alkyl, aryl and alkenyl are as previously defined (7) a heterocyclic group containing at least one atom of oxygen, nitrogen or sulfur. Said meanings (1) to (7) of A being unsubstituted or substituted with hydroxy, oxo, alkoxy, aryloxy, halo, cyano, isocyano, carboxy, carbamyloxy, amino, formyl, acyl, acyloxy, acylamino, sulfinyl, sulfonyl, phosphino, phosphinyl, phosphonyl, mercapto, alkylthio, arylthio, silyl, silyloxy, silylthio, nitro or azido; (8) a glycosyl residue (9) a glycopeptide (10) a glycoprotein (11) a glycolipid (12) a halogen, carboxy or sulfonyl and where R 4 , R 5 and R 6 are the same or different and are (a) where R 7 and R 8 are the same or different and are (1) hydrogen (2) B (3) D (b) hydroxyl, with the proviso that at least two of R 4 , R 5 and R 6 are and further in the ester case, at least one of R 1 , R 2 , R 3 , R 7 or R 8 is an esterifying group, while in the ether case at least one of R 1 , R 2 and R 3 is an etherifying group. In the context of the present description, the general terms used above have the following meanings, radicals and compounds that are termed "lower" containing up to and including 7, preferably up to and including 4 carbon atoms: Alkyl with 1 to 24 carbon atoms is for example, lower alkyl such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tributyl, sec.-butyl or tert.-butyl, also n-pentyl, neopentyl, n-hexyl or n-heptyl or higher alkyl such as straight-chain or branched octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, eicosyl, docosyl and n-tetracosyl; Cycloalkyl with 3 to 16 carbon atoms is, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl and adamantyl; Alkenyl with 2 to 24 carbon atoms is, for example, lower alkenyl such as vinyl, allyl, propenyl, butenyl, pentenyl and hexenyl or higher alkenyl such as octadienyl, octenyl, decenyl, dodecenyl, tetradecenyl, hexadecenyl, octadecenyl, octadecadienyl, octadecatrienyl, nonadecenyl and arachidonyl; Cycloalkenyl with 4 to 16 carbon atoms is, for example, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cyclooctenyl, cyclooctadienyl and cyclooctatrienyl; Aryl with 6 to 24 carbon atoms is, for example, phenyl, biphenyl, terphenyl, naphtyl, anthracenyl, phenanthrenyl; The radical A can be a heterocyclic group containing at least one atom selected from the group of oxygen, nitrogen and sulphur and is for example pyridyl, pyrrolyl, pyrrolidinyl, piperidinyl, indolyl, imidazolyl, furyl, dioxolanyl, oxiranyl, thiiranyl, thiopyranyl, oxazolyl and thiazolyl. The above mentioned radicals are unsubstituted or substituted. The substitution could consist of free functional groups such as hydroxyl, carbonyl, carboxyl, mercapto or amino or these groups could be present in protected form. Thus, carboxyl groups are usually protected in esterified form and contain as esterifying groups especially lower alkyl groups, which could be branched in the 1-position or suitably substituted in the 1- or 2-position. Preferred carboxyl groups protected in esterified form are inter alia methoxycarbonyl, butoxycarbonyl, tert. alkoxycarbonyl, for example tert. butoxycarbonyl, arylmethoxycarbonyl having one or two aryl radicals, these being especially phenyl radicals optionally substituted for example by lower alkyl, lower alkoxy, hydroxy, halogen and/or nitro, such as benzyloxycarbonyl, methoxybenzyloxycarbonyl, diphenylmethoxycarbonyl, 2-bromoethoxycarbonyl or 2-iodoethoxycarbonyl. Further preferred protected carboxyl groups in esterified form are silyloxycarbonyl groups, especially organic silyloxycarbonyl groups. In these the silicon atom contains as substituent preferably lower alkyl, especially methyl, also alkoxy, especially methoxy and/or halogen, for example chlorine. Suitable silyl-protecting groups are for example trimethylsilyl and dimethyl-tert.-butylsilyl. A protected amino group may be, for example, in the form of an acylaminogroup or in the form of arylalkylamino group or azido group or sulphonated amino group. In a corresponding acylamino group acyl is for example the acyl radical of an organic carboxylic acid having for example up to 18 carbon atoms, especially of an alkanecarboxylic acid that is preferably substituted for example by halogen or aryl or of a carbonic acid semiester. Such acyl groups are for example lower alkanoyl such as formyl or acetyl; halo-lower alkanoyl such as 2-chloro- and 2-bromoacetyl or lower alkoxycarbonyl straight or branched in the 1-position of the lower alkyl radical or suitably substituted in the 1- or 2-position, for example tert. butyl carbonyl; arylmethoxycarbonyl having one or two aryl radicals that are unsubstituted or, in the case of phenyl, may be substituted for example by lower alkyl, especially tert. lower alkyl, lower alkoxy, hydroxy, halogen and/or nitro; such as unsubstituted or substituted aryloxycarbonyl, for example benzyloxycarbonyl or 4-nitrobenzyloxycarbonyl or diphenylmethoxycarbonyl, for example benzhydroxycarbonyl or di-(4-methoxyphenyl)-methoxycarbonyl; aroylmethoxycarbonyl for example phenacyloxycarbonyl in which the aroyl group is benzoyl that is unsubstituted or substituted for example by halogen; halo-lower alkoxycarbonyl, for example 2-bromo- or 2-iodoethoxycarbonyl; or 2-(trisubstituted silyl)-ethoxycarbonyl such as for example 2-trimethylsilylethoxycarbonyl or 2-triphenylsilylethoxycarbonyl. An arylalkylamino group is a mono-, di- or especially a triarylalkylamino group in which the aryl radicals are especially unsubstituted or substituted phenyl radicals. Such groups are for example benzylamino, diphenylmethylamino or tritylamino. Amino grups may also contain organic silyl groups as protecting groups. Suitable silylprotecting groups are especially tri-lower alkylsilyl, such as trimethylsilyl and dimethyl-tert.-butylsilyl. Preferred aminoprotecing groups are acyl radicals of carbonic acid semiesters especially tert.-butoxycarbonyl or aryloxycarbonyl that is unsubstituted or substituted for example by benzyloxycarbonyl or 4-nitrobenzyloxycarbonyl or diphenylmethoxycarbonyl or 2.2.2-trichloroethoxycarbonyl. Other protected amino groups are sulphonated amino groups such as lower alkyl sulphonamides especially N-methyl sulphonamide and N-butylsulphonamide. Hydroxy- and mercapto-protecting groups are for example acyl radicals such as lower alkanoyl that is unsubstituted or substituted, for example by halogen, such as 2.2-dichloroacetyl or especially the acyl radicals of carbonic acid semiesters mentioned in connection with the amino-protecting groups and also etherifying groups such as tert.-butyl or 2-oxa- or 2-thia-aliphatic hydrocarbon radicals, for example 1-methoxyethyl, 1-methyl-thiomethyl or 2-oxa- or 2-thia-cycloaliphatic hydrocarbon radicals, for example 2-tetrahydrofuryl or 2-tetrahydropyranyl or corresponding thia analogues and unsubstituted or substituted benzyl, diphenylmethyl there coming into consideration as substituents of the phenyl radicals, for example halogen, lower alkoxy and/or nitro. Hydroxy and mercapto groups may also be protected in the form of corresponding organic silyloxy or silylthio groups. Suitable silyl protecting groups are especially lower alkylsilyl such as trimethylsilyl or dimethyl-tert.-butyl-silyl. Two free functional groups may also be substituted by a common protecting group. Thus, for example hydroxy groups may be substituted by a methylene radical that is unsubstituted or preferably substituted for example by lower alkyl, such as methyl or aryl, such as phenyl or such as methylene, isopropylidene, propylidene or benzylidene. The substitutions on the radical A could also consist of a halogen especially fluorine, chlorine and iodine and further by a cyano group. The radical A could also be substituted with phosphorus containing radicals, such as phosphine, phosphinyl and phosphonyl and with nitrogen containing radicals such as nitro or azido. One or two or three of R 1 , R 2 and R 3 can independently be etherified hydroxyl with the substituent B. Preferably B is a straight or branched alkyl, especially a lower alkyl such as methyl, ethyl or butyl or a higher alkyl such as octyl, decyl, dodecyl or eicosyl or an alkenyl especially vinyl, allyl or butenyl. Preferably B can also be a cycloalkyl, especially cyclopropyl or cyclohexyl or a cycloalkenyl, especially cyclopentenyl or cyclooctadienyl. In another preferred form, B is an aryl, especially phenyl, biphenyl and naphtyl. B can also be an etherified hydroxyl with a carbon radical which is a glycosyl residue. The glycosyl residue is derived for example from a monosaccharide such as erythrose, ribose, arabinose, allose, altrose, glucose, mannose, threose, xylose, lyxose, gulose, idose, galactose, talose, fructose or from a polysaccharide such as maltose,lactose, cellobiose or sucrose or nonhydrolyzed or partially hydrolyzed cellulose, amylose or amylopectin. Preferably the glycosyl residue is derived from glucose, fructose, mannose or lactose. The glycosyl residue could also be substituted with for example carboxyl, amino- or phosphonyl groups such as glucoseamine or galactoseamine or glucosephosphate or glucopyranosyl phosphate or sialic acid. B can also be an etherified hydroxyl with a carbon radical which is a glycopeptide. This radical is derived for example from one or more sugar residues which are attached primarily to serine, threonine or aspargine side chains of the peptide, where the peptide is formed by different combinations of amino acids up to a molecular weight of 10,000. Prefered radicals are those which include glucoseamine or galactoseamine attached to especially di- and tripeptides. B can also be an etherified hydroxyl with a carbon radical which is a glycoprotein. This radical is derived for example from one or more sugar residues which are attached primarily to serine, threonine or aspargine side chains of the proteins, especially alkaline phosphatase, acetylcholinesterase, 5-nucleotidase, Thy-1, Th B and heparan sulphate proteoglycan. Preferred radicals are those which include glucoseamine and galactoseamine attached to the protein. Especially preferred radicals are lectins such as concanavalin A, wheat germ agglutinin, peanutagglutinin and seromucoid and orosomucoid. B can also be an etherified hydroxyl with a carbon radical which is glycolipid. This radical is derived for example from one or more sugar residues which are attached to a lipid. Preferred radicals are those which include glucose or galactose. Further preferred radicals are cerebroside and ganglioside. B can also be a halogen, carboxy or sulfonyl. One or two or three of R 1 , R 2 and R 3 can independently be esterified hydroxyl with the substituent A as defined previously. Preferably the radical is derived from an organic carboxylic acid, especially an aliphatic, but also a cycloaliphatic, cycloaliphatic-aliphatic, aromatic or araliphatic carboxylic acid. Aliphatic carboxylic acids are inter alia alkane carboxylic acids that are unsubstituted or substituted for example by hydroxy or etherified or esterified hydroxy such as lower alkoxy or lower alkanoyloxy, by unsubstituted or substituted amino, such as lower alkylamino, di-lower alkylamino or by acylamino for example alkanoylamino and corresponding alkene- or alkyne carboxylic acids that may have one or more double or triple bonds. Preferably the radical is unsubstituted or hydroxysubstituted lower alkanecarboxylic acid such as acetic acid, butyric acid, caproic acid or 2-hydroxybutyric acid or unsubstituted or hydroxysubstituted higher alkanecarboxylic acid such as lauric acid or stearic acid. Preferably the radical is also a lower alkene- and lower alkyne-carboxylic acid such as acrylic acid or crotonic acid or higher alkene- and higher alkyne-carboxylic acid such as oleic acid and arachidonic acid. In cycloaliphatic-aliphatic radicals the cycloaliphatic moiety and the aliphatic moiety have the meanings described above and are especially monocyclic or polycyclic cyclo-lower alkyl. Aromatic and araliphatic carboxy acids are inter alia benzoic or phenyl-lower alkanecarboxylic that are unsubstituted or substituted for example by alkyl, hydroxy, lower alkoxy or halogen. Preferably the radical is benzoic acid or phenolacetic acid. A can also be an esterified hydroxy with a carbon radical which is a carboxy group to form a semiester or a diester. Preferred carboxy groups are lower alkane carboxyl such as acetoxy and butyryloxy. A can also be an esterified hydroxyl with a radical containing nitrogen such as amino. Preferably the radical is lower alkylamino for example methylamino, ethylamino and isopropylamino. One or two or three of R 1 , R 2 and R 3 can independently be esterified hydroxyl with the substituent D. D can be an amino acid, for example lysine, histidine, asparagine, arginine, aspartic acid, threonine, serine, glutamic acids proline, glycine, alanine, cystine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine or tryptophan. Preferably the amino acid is alanine, serine, glycine, threonine, methionine, asparagine and histidine. D can also be a peptide consisting of the above mentioned amino acids up to a molecular weight of 10,000. Preferred radicals are dipeptides such as alanyl-alanyl, prolyl-methionyl, glycyl-glycyl or threonyl-histidyl. D can also be a protein such as albumin, antitrypsin, macroglobulin, haptoglobin, caeruloplasmin, transferrin, α- or β-lipoprotein, β- or γ-globulin or fibrinogen. E can consist of phosphorus containing radicals such as phosphorothioate. E can further consist of sulphur containing radicals such as xanthate, sulfinyl or sulfonyl. E can further also be a carbamoyl group. Two or three of R 4 , R 5 and R 6 could independently be a phosphorus containing radical with the formula R 7 and R 8 can independently be hydrogen or B as defined previously. Preferably when R 7 and/or R 8 is B the radical is alkyl or aryl especially lower alkyl such as methyl, ethyl or butyl or higher alkyl such as octyl or dodecyl or aryl such as phenyl. In another preferred form B is substituted alkyl such as dihydroxy propyl or esterified dihydroxypropyl. In another preferred form R 7 is hydrogen and R 8 is lower alkyl especially methyl, ethyl or butyl. One embodiment of this invention relates to an ester or ether of myo-inositol having the above Formula wherein R 1 , R 2 and R 3 independently are: a) hydroxyl or b) OB, where B is as defined previously wherein R 4 , R 5 and R 6 independently are as defined previously. In this embodiment R 1 or preferably R 1 and R 2 are hydroxyl, while R 2 and R 3 or preferably only R 3 are etherified hydroxyl with the substituent B, where B is a glycosyl residue, a glycopeptide, a glycoprotein, a glycolipid or selected from the group of halogen, carboxy, phosphonyl or sulphonyl. B is preferably a straight or branched alkyl, especially a lower alkyl such as methyl, ethyl or butyl or a higher alkyl such as octyl, dodecyl and eicosyl or an alkenyl, especially vinyl, alkyl or butenyl. Preferably, B can also be a cycloalkyl, especially cyclopropyl or cyclohexyl or aryl, especially phenyl, biphenyl or naphtyl. The above mentioned radicals can be unsubstituted or substituted especially with hydroxyl, mercapto, carboxyl, amino or phosphino. By preference B can also be a glycosyl residue especially glucose, mannose, maltose, glucoseamine or glucosephosphate; or a glycopeptide especially a glycopeptide including glucoseamine or galactoseamine attached to di- and tripeptides such as alanyl-alanyl, prolyl-methionyl or glycyl-glycyl; or a glycoprotein, especially a glycoprotein including glucoseamine or galactoseamine attached to a protein such as concanavalin A, wheat germ agglutinin and peanutagglutinin; or a glycolipid especially a glycolipid including glucose or galactose such as cerebroside and ganglioside. In another preferred form of this invention R 1 , R 2 and R 3 are the same i.e. etherified hydroxyls with the carbon radical B as previously defined. R 4 , R 5 and R 6 are respectively, where R 7 and R 8 are as defined previously. Most preferably R 4 , R 5 and R 6 are where Y is oxygen and R 7 and R 8 are hydrogen or alkyl such as methyl, ethyl or butyl or aryl such as phenyl. In this embodiment of the invention R 1 , R 2 and R 3 are the same, that is etherified hydroxyl with the substituent B, which preferably is a straight or branched alkyl, especially a lower alkyl such as methyl, ethyl or butyl or a higher alkyl such as octyl, dodecyl or eicosyl or an alkenyl, especially vinyl, alkyl or butenyl. Preferably, B can also be a cycloalkyl, especially cyclopropyl or cyclohexyl or aryl, especially phenyl, biphenyl or naphtyl. The above mentioned radicals can be unsubstituted or substituted, especially with hydroxyl, mercapto, carboxyl, amino or phosphino. By preference, B can also be a glycosyl residue, especially glucose, mannose, maltose, glucoseamine or glucosephosphate; or a glycopeptide, especially a glycopeptide including glucoseamine or galactoseamine attached to di- and tripeptides such as alanyl-alanyl, prolyl-methionyl or glycyl-glycyl; or a glycoprotein, especially a glycoprotein including glucoseamine or galactoseamine attached to a protein such as concanavalin A, wheat germ agglutinin and peanutagglutinin; or a glycolipid especially a glycolipid including glucose or galactose such as cerebroside and ganglioside. In one of the most preferred embodiments of this type of the invention R 1 and R 2 are hydroxyl and R 3 is as described above and R 4 , R 5 and R 6 are where Y is oxygen and R 7 and R 8 are hydrogen: In this formula -OB and the two hydroxyls could be in changed positions independently to each other B is especially selected from the group of straight or branched alkyl such as methyl, butyl, dodecyl or eicosyl or alkenyl such as allyl or butenyl or cycloalkyl such as cyclopropyl or cyclohexyl or aryl such as phenyl unsubstituted or substituted especially with hydroxyl, mercapto, carboxyl, amino or phosphino; or selected from the group of a glycosyl residue especially glucose, mannose, glucoseamine or glucosephosphate or a glycopeptide especially including a glucoseamine or galactoseamine attached to a di- or tripeptide, or a glycoprotein especially including a glucoseamine or galactoseamine attached to the protein or a glycolipid including glucose or galactose; or selected from the group of halogen, especially fluorine or chlorine, or carboxy, phosphonyl or sulphinyl; or selected from the group consisting of repeated fragments of hydroxyl groups etherified with carbon radicals such as polyethyleneglycol or polypropyleneglycol. In another form of this most preferred embodiment of this type of the invention R 1 and R 2 are hydroxyl and R 3 is as described above and R 4 , R 5 and R 6 are where Y is oxygen and where R 7 and R 8 preferably are lower alkyl such as methyl and butyl: In another of the most preferred embodiments of this type of the invention R 1 , R 2 and R 3 are the same and as described above and R 4 , R 5 and R 6 are where Y is oxygen and R 7 and R 8 are hydrogen: B is especially selected from the group of straight or branched alkyl, such as methyl, butyl, dodecyl or eicosyl or alkenyl such as allyl or butenyl or cycloalkyl such as cyclopropyl or cyclohexyl or aryl such as phenyl, unsubstituted or substituted especially with hydroxyl, mercapto, carboxyl, amino or phosphino; or selected from the group of glycosyl residues especially glucose, mannose, glucoseamine or glucosephosphate or a glycopeptide especially including a glucoseamine or galactoseamine attached to a di- or tripeptide, or a glycoprotein especially including a glucoseamine or galactoseamine attached to the protein or a glycolipid including glucose or galactose. In another form of this most preferred embodiment of this type of the invention R 1 , R 2 and R 3 are the same and as described above and R 4 , R 5 and R 6 are where Y is oxygen and where R 7 and R 8 preferably are lower alkyl such as methyl and butyl: One embodiment of this invention relates to an ether or ester of myo-inositol wherein R 1 , R 2 and R 3 independently are a) hydroxyl or b) where A is as defined previously or c) D, where D is as defined previously, where R 4 , R 5 and R 6 independently are as defined previously. In this embodiment R 1 or preferably R 1 and R 2 are hydroxyl while R 2 and R 3 or preferably only R 3 are selected from the group of esterified hydroxyl with the substituents A or D, where A is as defined previously, and where D is an amino acid, peptide or a protein. Preferably, D is an amino acid, especially asparginine, histidine, methionine and serine or a peptide consisting of amino acids up to a molecular weight of 10,000, especially dipeptides such as alanyl-alanyl, prolyl-methionyl and glycyl-glycyl or a protein, especially albumin, transferrin, α- and β-lipoprotein, β- and γ-globulin and fibrinogen. In another preferred form of this invention R 1 , R 2 and R 3 are the same and selected from: a) where A is as defined previously or b) D, where D is as defined previously R 4 , R 5 and R 6 are and/or OH respectively, where R 7 and R 8 are as defined previously. Preferably, R 4 and R 5 are while R 6 is OH Most preferably R 4 , R 5 and R 6 are where R 7 and R 8 are hydrogen or alkyl, such as methyl, ethyl or butyl or aryl such as phenyl. In this embodiment of the invention R 1 , R 2 and R 3 are the same, that is esterified hydroxyl with the substituents A or D. Preferably, D is an amino acid, especially asparagine, histidine, methionine and serine or a peptide consisting of amino acids up to a molecular weight of 10,000, especially dipeptides such as alanyl-alanyl, prolyl-methionyl and glycyl-glycyl or a protein, especially albumin, transferrin, α-and β-lipoprotein, β- and γ-globulin and fibrinogen. In one of the most preferred embodiments of this type of the invention R 1 and R 2 are hydroxyl and R 3 is as described above and R 4 , R 5 and R 6 are where Y is oxygen and R 7 and R 8 are hydrogen: In this formula or D and the two hydroxyls could be in changed positions independently to each other. D is especially selected from the group of amino acids, such as asparagine, histidine, methionine or serine or selected from the group of peptides such as alanyl-alanyl, or prolyl-methionyl or selected from the group of proteins, such as albumin, transferrin and α- and β-lipoprotein. In another form of this most preferred embodiment of this type of the invention R 1 and R 2 are hydroxyl and R 3 is as described above and R 4 , R 5 and R 6 are where Y is oxygen and where R 7 and R 8 preferably are lower alkyl such as methyl and butyl: In another form of this most preferred embodiment of this type of the invention R 1 , R 2 and R 3 are the same and as described above and R 4 , R 5 and R 6 are where Y is oxygen and R 7 and R 8 are hydrogen: In another from of this most preferred embodiment of this type of the invention R 1 , R 2 and R 3 are the same and as described above and R 4 , R 5 and R 6 are where Y is oxygen and where R 7 and R 8 preferably are lower alkyl such as methyl and butyl: One embodiment of this invention relates to a compound of Formula (I), wherein R 1 , R 2 and R 3 independently are as defined previously and where X is a radical of myo-inositol or a radical of a configuration isomer thereof and where R 4 , R 5 and R 6 are where Y, R 7 and R 8 are as defined previously. Y is oxygen and R 7 and R 8 are independently hydrogen or the radical B, especially unsubstituted alkyl such as methyl, ethyl, butyl, octyl or dodecyl or aryl such as phenyl or substituted alkyl such as dihydroxypropyl or esterified dihydroxypropyl; or D, especially an amino acid such as methionine or glycine. In one of the most preferred embodiments of this type of the invention R 1 , R 2 and R 3 are hydroxyl and R 4 , R 5 and R 6 are Preferably, R 7 and/or R 8 are esterified dihydroxypropyl, especially with C 14 to C 20 alkylcarbonyl groups; or glycine, methionine or histidine. In another of the most preferred embodiments of this invention R 1 , R 2 and R 3 are hydroxyl and R 4 and R 5 are and R 6 is OH. In this formula OH and R 4 and R 5 could be in changed positions independently to each other Preferably, R 7 and/or R 8 are hydrogen or methyl, ethyl, butyl, octyl, dodecyl, phenyl, dihydroxypropyl or esterified dihydroxypropyl, especially with C 14 to C 20 -alkyl carbonyl groups; or glycine, methionine or histidine, The described compounds can also exist in dimeric or polymeric forms. The described substituents could per se be e.g. pharmaceutically active compounds. The invention also relates to a composition comprising one or more compounds of Formula (I) as defined previously. The composition usually contains 10 to 99.5 %, preferably 20 to 99.5 % of these compounds. The invention relates to the above mentioned compounds as pharmaceutically active substances, their use for the manufacture of pharmaceutical preparations and to pharmaceutical preparations containing these compounds. The invention also relates to the above mentioned compounds as additives for foodstuffs or stabilizers for different products. The present invention particularly aims at a method of reducing the negative effect of various metal ions, e.g. cadmium, aluminium, lead, mercury, nickel or chromium ions or free radicals in the body tissues. Said method comprises administering to a person or an animal, i.e. mammals, an amount of inventive compounds to interfere with such metal ion or inhibit or reduce the formation of free radicals in the body. The invention also comprises a method of preventing or alleviating one of the following conditions: an arthritic condition, bronchitis, a cell proliferation change, a cancer, high blood pressure, a cardiovascular disease, age diabetes, damage to the placenta, damage to the testicles, damage of different parts of the eye such as retina tissue and lens, damage to the prostate, damage to cell membranes, damage to the central nervous system, damage to the conducting system of the heart, emphysema, lung fibrosis, migraine headache, menstruation disorders, endothelium damage, kidney damage, thrombosis, multiple sclerosis, increased platelet aggregation, inhibition of the prostacycline production, metal intoxication, allergy caused by lead, mercury, nickel or chromium, inflammatory conditions, damage to the connective tissue, liver damage, brain damage, immuno-deficiency, conditions of shock, gastroenteritis, dermatitis and neurological disturbance. Said conditions are attributable to or are caused or aggravated by the presence of metal ions or free radicals in the body. The method comprises administering to a human or an animal an amount of a chosen compound sufficient to obtain said prevention or alleviation. Furthermore, the invention covers a method of alleviating the detrimental effect of radiation in the body, which method comprises administering to a human or an animal an amount of the inventive compound sufficient to alleviate said effect of radiation. For instance the radiation can be X-ray or nuclear radiation, but other kinds of radiation are also contemplated. The following examples illustrate the invention but do not restrict it in any way. Example 1 Two hundred µmol of D-myo-inositol-1,2,6-triphosphate in acid form was freeze-dried in a vial. Four hundred mg sodium hydroxide (NaOH) was dissolved in 10 ml dimethylsulphoxide (DMSO) and added to the vial. Two ml methyliodide was added and the mixture was stirred under dry nitrogen atmosphere for one hour. After neutralization with 1.0 M sodiumhydroxide an excess of calciumchloride was added to give a precipitate of the formed methyleter. Structural determination with NMR and IR showed the product to be the trimethylether of D-myo-inositol-1,2,6-triphosphate. Example 2 One hundred ml of a solution of the sodiumsalt of myo-inositol-1,2,3-triphosphate with a concentration of 0.05 M was added to 100 ml of a mixture of 15 % aqueous sodium bisulphate and ethyl alcohol at room temperature. The mixture was neutralized with 1.0 M sodiumhydroxide and calciumchloride was added to give a precipitate of the calciumsalt of the formed ethylether. Structural determination with NMR and IR showed the product to be the triethylether of myo-inositol-1,2,3-triphosphate. Example 3 Five hundred mg D-myo-inositol-1,2,6-triphosphate in acid form was mixed with five ml acetylchloride-trifluoracetic acid (1:2) at room temperature. The mixture was sonicated for 60 hrs and then evaporated to dryness. Structural determination showed the product to be D-3,4,5-tri-O-acetyloxy-myo-inositol-1,2,6-triphosphate. Example 4 Five ml of a 80 % solution of D-myo-inositol-1,2,6-triphosphoric acid was added to 10 ml of dodecanoic acid at room temperature. The mixture was stirred for two hours and then neutralized with 0.1 M sodium hydroxide. Six grams of calcium chloride was added to give a precipitate of the calciumsalt of the formed dodecylester. Structural determination with NMR and IR showed the product to be the monododecylester of D-myo-inositol--1,2,6-triphosphate. Example 5 Five hundred mg D-myo-inositol-1,2,6-triphosphate in freeze-dried form was mixed with 1.0 ml concentrated sulphuric acid at 0°C for 30 min. Excess of sulphuric acid was removed by gelchromatography and the resulting purified compound was shown to be D-3,4,5-trisulpho-myo-inositol-1,2,6-triphosphate. Example 6 To two hundred mg of the sodiumsalt of D-myo-inositol-1,2,6--triphosphate was added five ml 5.0 M sodium hydroxide in a closed vial. Excess of carbon disulfide was introduced and maintained at 40°C for three hrs under stirrig. The mixture was evaporated and the resulting compound was identified as the xanthate ester of D-myo-inositol-1,2,6--triphosphate. Example 7 One hundred µmol of D-myo-inositol-1,2,6-triphosphate was mixed with 600 mg sodiumhydroxide in two ml water. To this solution 550 mg sodiumchloracetate was added and the reaction mixture was heated to 70°C for 5 hrs. After cooling to room temperature the mixture was neutralized with 2.0 M hydrochloric acid and calcium chloride was added to give a precipitate, which was shown to be D-3,4,5-tri-O-carboxy-myo-inositol-1,2,6--triphosphate. Example 8 Five ml of a 80 % solution of D-myo-inositol-1,2,6-triphosphate in acid form was added to the cesium salt of glycine (2.5 g) and further 1.0 ml of concentrated sulphuric acid was added. The mixture was stirred for two hours in room temperature and then neutralized with 1.0 M NaOH. Six grams of calcium chloride was added to give a precipitate which was shown to be the monoglycyl ester of D-myo-inositol-1,2,6-triphosphate. Example 9 1.0 g of the tetrabutylammoniumsalt of D-myo-inositol-1,2,6--triphosphate was dissolved in chloroform. Galactose (850 mg) and anhydrous hydrogen chloride (1.0 ml) was added and the mixture was heated under reflux for 12 hours. After cooling to room temperature the mixture was purified with gelchromatography (silica gel) and a compound determined by NMR to be 4-O-galactosyl-myo-inositol-1,2,6-triphosphate was isolated. Example 10 One hundred mg of D-myo-inositol-1,2,6-triphosphate was freeze-dried in a vial. One ml of N,O-bis(trimethylsilyl)trifluoracetamide-chlorotrimethylsilane-pyridine (9:9:10;v:v:v) was added and taken to dryness under a stream of nitrogen and then dissolved in 1.0 ml of 10 % anhydrous methanol in diethyl ether at 0°C. After 15 minutes the mixture was evaporated and structural determination of the residue showed it to be D-3,4,5-tri-O-trimethylsilyl-myo-inositol--1,2,6-triphosphate. Example 11 Tablets of calcium salt of triethylether of myo-inositol-1,2,3-triphosphate. Tablets of the calcium salt of triethylether of myo-inositol-1,2,3-triphosphate were produced in the following way. 50 g calcium salt of triethylether of myo-inositol-1,2,3-triphosphate, 132 g lactose and 6 g acacia were mixed. Purified water was then added to the mixture, whereupon the mixing was continued until a suitable consistency was obtained. The mixture was sieved and dried. Then the mixture was blended with 10 g talcum and 2 g magnesium stearate. The mixture was compressed into tablets each weighing 200 mg. Example 12 Tablets of calcium salt of monododecylester of D-myo-inositol-1,2,6-triphosphate. Tablets of the calcium salt of monododecylester of D-myo-inositol-1,2,6-triphosphate were produced in the following way. 50 g calcium salt of monodedecylester of D-myo-inositol-1,2,6-triphosphate, 132 g lactose and 6 g acacia were mixed. Purified water was then added to the mixture, whereupon the mixing was continued until a suitable consistency was obtained. The mixture was sieved and dried. Then the mixture was blended with 10 g talcum and 2 g magnesium stearate. The mixture was compressed into tablets each weighing 200 mg. In those cases where the compounds of the present invention are soluble, solutions suitable for injection can easily be prepared too.

Claims: Claims for the following Contracting States : AT, BE, CH, LI, DE, FR, IT, LU, NL, SE An ester or an ether of myo-inositol phosphate having the structural formula where R 1 , R 2 and R 3 are the same or different and are (a) hydroxyl (b) where A is (1) a straight or branched chain alkyl containing 1 to 24 carbon atoms, (2) cycloalkyl containing 3 to 16 carbon atoms, (3) alkenyl containing 2 to 24 carbon atoms, (4) cycloalkenyl containing 5 to 16 carbon atoms, (5) aryl containing 6 to 24 carbon atoms, (6) aralkyl, alkaryl, aralkenyl or alkenylaryl wherein alkyl, aryl and alkenyl are as previously defined, (7) a heterocyclic group containing at least one atom of oxygen, nitrogen or sulfur. Said meanings (1) to (7) of A being unsubstituted or substituted with hydroxy, oxo, alkoxy, aryloxy, halo, cyano, isocyano, carboxy, amino, formyl, acyl, acyloxy, acylamino, sulfinyl, sulfonyl, phosphino, phosphinyl, phosphonyl, mercapto, alkylthio, arylthio, silyl, silyloxy, silylthio, nitro or azido; (8) carboxy (9) amino (c) D, where D is (1) an amino acid (2) a peptide or (3) a protein including a lipoprotein and a nucleoprotein (d) E, where E is (1) carbamoyl (2) sulfinyl or sulfonyl (3) xanthate or phosphorothioate (e) -O-B, where B is (1) straight or branched chain alkyl containing 1 to 24 carbon atoms, (2) cycloalkyl containing 3 to 16 carbon atoms, (3) alkenyl containing 2 to 24 carbon atoms, (4) cycloalkenyl containing 5 to 16 carbon atoms, (5) aryl containing 6 to 24 carbon atoms, (6) aralkyl, alkaryl, aralkenyl or alkenylaryl wherein said alkyl, aryl and alkenyl are as previously defined (7) a heterocyclic group containing at least one atom of oxygen, nitrogen or sulfur. Said meanings (1) to (7) of B being unsubstituted or substituted with hydroxy, oxo, alkoxy, aryloxy, halo, cyano, isocyano, carboxy, carbamyloxy, amino, formyl, acyl, acyloxy, acylamino, sulfinyl, sulfonyl, phosphino, phosphinyl, phosphonyl, mercapto, alkylthio, arylthio, silyl, silyloxy, silylthio, nitro or azido; (8) a glycosyl residue (9) a glycopeptide (10) a glycoprotein (11) a glycolipid (12) a halogen, carboxy or sulfonyl and where R 4 , R 5 and R 6 are the same or different and are (a) where R 7 and R 8 are the same or different and are (1) hydrogen (2) B (3) D (b) hydroxyl, with the proviso that at least two of R 4 , R 5 and R 6 are and further in the ester case, at least one of R 1 , R 2 , R 3 , R 7 or R 8 is an esterifying group, while in the ether case at least one of R 1 , R 2 and R 3 is an etherifying group. A compound in accordance with claim 1 wherein R 1 , R 2 and R 3 are hydroxyl; and R 4 , R 5 and R 6 are where R 7 is acyloxyalkyl; and R 8 is hydrogen or acyloxyalkyl. A compound in accordance with claim 1 wherein R 1 , R 2 , R 3 and R 4 are hydroxyl; and R 5 and R 6 are where R 7 is acyloxyalkyl; and R 8 is hydrogen or acyloxyalkyl. A compound in accordance with claim 1 wherein R 1 , R 2 , and R 3 are hydroxyl; and R 4 , R 5 and R 6 are where R 7 is a straight or branched chain alkyl containing 1 to 24 carbon atoms, cycloalkyl containing 3 to 16 carbon atoms or aryl containing 6 to 24 carbon atoms; and R 8 is hydrogen, straight or branched chain alkyl containing 1 to 24 carbon atoms, cycloalkyl containing 3 to 16 carbon atoms or aryl containing 6 to 24 carbon atoms. A compound in accordance with claim 1 wherein R 1 , R 2 , R 3 and R 4 are hydroxyl; and R 5 and R 6 are where R 7 is a straight or branched chain alkyl containing 1 to 24 carbon atoms, cycloalkyl containing 3 to 16 carbon atoms or aryl containing 6 to 24 carbon atoms; and R 8 is hydrogen, straight or branched chain alkyl containing 1 to 24 carbon atoms, cycloalkyl containing 3 to 16 carbon atoms or aryl containing 6 to 24 carbon atoms. A compound in accordance with claim 1 wherein R 1 , R 2 , and R 3 are and R 4 , R 5 and R 6 are where R 7 and R 8 are the same or different and are hydrogen, acyloxyalkyl, straight or branched chain alkyl containing 1 to 24 carbon atoms, cycloalkyl containing 3 to 16 carbon atoms or aryl containing 6 to 24 carbon atoms. A compound in accordance with claim 1 wherein R 1 and R 3 are hydroxyl; R 2 is and R 4 , R 5 and R 6 are where R 7 and R 8 are the same or different and are hydrogen, acyloxyalkyl, straight or branched chain alkyl containing 1 to 24 carbon atoms, cycloalkyl containing 3 to 16 carbon atoms or aryl containing 6 to 24 carbon atoms. A compound in accordance with claim 1 wherein R 1 and R 3 are hydroxyl; R 2 is D; and R 4 , R 5 and R 6 are where R 7 and R 8 are the same or different and are hydrogen, acyloxyalkyl, straight or branched chain alkyl containing 1 to 24 carbon atoms, cycloalkyl containing 3 to 16 carbon atoms or aryl containing 6 to 24 carbon atoms. A compound in accordance with claim 1 wherein R 1 and R 3 and R 4 are hydroxyl; R 2 is D; and R 5 and R 6 are where R 7 and R 8 are the same or different and are hydrogen, acyloxyalkyl, straight or branched chain alkyl containing 1 to 24 carbon atoms, cycloalkyl containing 3 to 16 carbon atoms or aryl containing 6 to 24 carbon atoms. A compound in accordance with claim 1 wherein R 1 , R 2 , and R 3 are -O-B; and where R 4 , R 5 and R 6 are where R 7 and R 8 are the same or different and are hydrogen, acyloxyalkyl, straight or branched chain alkyl containing 1 to 24 carbon atoms, cycloalkyl containing 3 to 16 carbon atoms or aryl containing 6 to 24 carbon atoms. A compound in accordance with claim 1 wherein R 1 , and R 3 are hydroxyl and R 2 is -O-B; and where R 4 , R 5 and R 6 are where R 7 and R 8 are the same or different and are hydrogen, acyloxyalkyl, straight or branched chain alkyl containing 1 to 24 carbon atoms, cycloalkyl containing 3 to 16 carbon atoms or aryl containing 6 to 24 carbon atoms. A compound according to any one of the preceding claims in substantially pure form. A composition containing a compound according to any one of the preceding claims. A compound according to any one of the preceding claims for use as a pharmaceutically active ingredient in a pharmaceutical composition. The use of a compound according to any one of the preceding claims for preparing of a medicament. Claims for the following Contracting States : ES, GR Use of myo-inositol phosphate for the preparation of an ester or an ether having the structural formula where R 1 , R 2 and R 3 are the same or different and are (a) hydroxyl (b) where A is (1) a straight or branched chain alkyl containing 1 to 24 carbon atoms, (2) cycloalkyl containing 3 to 16 carbon atoms, (3) alkenyl containing 2 to 24 carbon atoms, (4) cycloalkenyl containing 5 to 16 carbon atoms, (5) aryl containing 6 to 24 carbon atoms, (6) aralkyl, alkaryl, aralkenyl or alkenylaryl wherein alkyl, aryl and alkenyl are as previously defined, (7) a heterocyclic group containing at least one atom of oxygen, nitrogen or sulfur. Said meanings (1) to (7) of A being unsubstituted or substituted with hydroxy, oxo, alkoxy, aryloxy, halo, cyano, isocyano, carboxy, amino, formyl, acyl, acyloxy, acylamino, sulfinyl, sulfonyl, phosphino, phosphinyl, phosphonyl, mercapto, alkylthio, arylthio, silyl, silyloxy, silylthio, nitro or azido; (8) carboxy (9) amino (c) D, where D is (1) an amino acid (2) a peptide or (3) a protein including a lipoprotein and a nucleoprotein (d) E, where E is (1) carbamoyl (2) sulfinyl or sulfonyl (3) xanthate or phosphorothioate (e) -O-B, where B is (1) straight or branched chain alkyl containing 1 to 24 carbon atoms, (2) cycloalkyl containing 3 to 16 carbon atoms, (3) alkenyl containing 2 to 24 carbon atoms, (4) cycloalkenyl containing 5 to 16 carbon atoms, (5) aryl containing 6 to 24 carbon atoms, (6) aralkyl, alkaryl, aralkenyl or alkenylaryl wherein said alkyl, aryl and alkenyl are as previously defined (7) a heterocyclic group containing at least one atom of oxygen, nitrogen or sulfur. Said meanings (1) to (7) of B being unsubstituted or substituted with hydroxy, oxo, alkoxy, aryloxy, halo, cyano, isocyano, carboxy, carbamyloxy, amino, formyl, acyl, acyloxy, acylamino, sulfinyl, sulfonyl, phosphino, phosphinyl, phosphonyl, mercapto, alkylthio, arylthio, silyl, silyloxy, silylthio, nitro or azido; (8) a glycosyl residue (9) a glycopeptide (10) a glycoprotein (11) a glycolipid (12) a halogen, carboxy or sulfonyl and where R 4 , R 5 and R 6 are the same or different and are (a) where R 7 and R 8 are the same or different and are (1) hydrogen (2) B (3) D (b) hydroxyl, with the proviso that at least two of R 4 , R 5 and R 6 are and further in the ester case, at least one of R 1 , R 2 , R 3 , R 7 or R 8 is an esterifying group, while in the ether case at least one of R 1 , R 2 and R 3 is an etherifying group. Use of myo-inositol phosphate for the preparation of an ester or an ether as described in claim 1 wherein R 1 , R 2 and R 3 are hydroxyl; and R 4 , R 5 and R 6 are where R 7 is acyloxyalkyl; and R 8 is hydrogen or acyloxyalkyl. Use of myo-inositol phosphate for the preparation of an ester or an ether as described in claim 1 wherein R 1 , R 2 , R 3 and R 4 are hydroxyl; and R 5 and R 6 are where R 7 is acyloxyalkyl; and R 8 is hydrogen or acyloxyalkyl. Use of myo-inositol phosphate for the preparation of an ester or an ether as described in claim 1 wherein R 1 , R 2 , and R 3 are hydroxyl; and R 4 , R 5 and R 6 are where R 7 is a straight or branched chain alkyl containing 1 to 24 carbon atoms, cycloalkyl containing 3 to 16 carbon atoms or aryl containing 6 to 24 carbon atoms; and R 8 is hydrogen, straight or branched chain alkyl containing 1 to 24 carbon atoms, cycloalkyl containing 3 to 16 carbon atoms or aryl containing 6 to 24 carbon atoms. Use of myo-inositol phosphate for the preparation of an ester or an ether as described in claim 1 wherein R 1 , R 2 , R 3 and R 4 are hydroxyl; and R 5 and R 6 are where R 7 is a straight or branched chain alkyl containing 1 to 24 carbon atoms, cycloalkyl containing 3 to 16 carbon atoms or aryl containing 6 to 24 carbon atoms; and R 8 is hydrogen, straight or branched chain alkyl containing 1 to 24 carbon atoms, cycloalkyl containing 3 to 16 carbon atoms or aryl containing 6 to 24 carbon atoms. Use of myo-inositol phosphate for the preparation of an ester or an ether as described in claim 1 wherein R 1 , R 2 , and R 3 are and R 4 , R 5 and R 6 are where R 7 and R 8 are the same or different and are hydrogen, acyloxyalkyl, straight or branched chain alkyl containing 1 to 24 carbon atoms, cycloalkyl containing 3 to 16 carbon atoms or aryl containing 6 to 24 carbon atoms. Use of myo-inositol phosphate for the preparation of an ester or an ether as described in claim 1 wherein R 1 and R 3 are hydroxyl; R 2 is and R 4 , R 5 and R 6 are where R 7 and R 8 are the same or different and are hydrogen, acyloxyalkyl, straight or branched chain alkyl containing 1 to 24 carbon atoms, cycloalkyl containing 3 to 16 carbon atoms or aryl containing 6 to 24 carbon atoms. Use of myo-inositol phosphate for the preparation of an ester or an ether as described in claim 1 wherein R 1 and R 3 are hydroxyl; R 2 is D; and R 4 , R 5 and R 6 are where R 7 and R 8 are the same or different and are hydrogen, acyloxyalkyl, straight or branched chain alkyl containing 1 to 24 carbon atoms, cycloalkyl containing 3 to 16 carbon atoms or aryl containing 6 to 24 carbon atoms. Use of myo-inositol phosphate for the preparation of an ester or an ether as described in claim 1 wherein R 1 and R 3 and R 4 are hydroxyl; R 2 is D; and R 5 and R 6 are where R 7 and R 8 are the same or different and are hydrogen, acyloxyalkyl, straight or branched chain alkyl containing 1 to 24 carbon atoms, cycloalkyl containing 3 to 16 carbon atoms or aryl containing 6 to 24 carbon atoms. Use of myo-inositol phosphate for the preparation of an ester or an ether as described in claim 1 wherein R 1 , R 2 , and R 3 are -O-B; and where R 4 , R 5 and R 6 are where R 7 and R 8 are the same or different and are hydrogen, acyloxyalkyl, straight or branched chain alkyl containing 1 to 24 carbon atoms, cycloalkyl containing 3 to 16 carbon atoms or aryl containing 6 to 24 carbon atoms. Use of myo-inositol phosphate for the preparation of an ester or an ether as described in claim 1 wherein R 1 , and R 3 are hydroxyl and R 2 is -O-B; and where R 4 , R 5 and R 6 are where R 7 and R 8 are the same or different and are hydrogen, acyloxyalkyl, straight or branched chain alkyl containing 1 to 24 carbon atoms, cycloalkyl containing 3 to 16 carbon atoms or aryl containing 6 to 24 carbon atoms. Use of myo-inositol phosphate for the preparation of an ester or an ether as described in any one of the preceding claims in substantially pure form. The use of an ester or an ether of myo-inositol phosphate as described in any one of the preceding claims for the preparation of a medicament.

Inventors: SIREN MATTI, SIREN, MATTI, Sirén, Matti
Applicants: PERSTORP AB
Application year: 1987
Main classification: C07F9
IPC codes: C07F9, C07K14, A61P7, A61P39, A61P29, A61P43, A61K31, C07H15, A61P9, A61P15, A61P1, A61P3, A61P25, A61P11, A61P13, C07F7, A61P35, A61P27, C07K16, A61P37